Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 8,000 shares, a decrease of 51.2% from the October 15th total of 16,400 shares. Based on an average trading volume of 28,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s stock are sold short.

Insider Transactions at Assembly Biosciences

In other news, major shareholder Alexander Schornstein purchased 10,000 shares of Assembly Biosciences stock in a transaction that occurred on Tuesday, October 8th. The shares were bought at an average cost of $14.58 per share, with a total value of $145,800.00. Following the completion of the purchase, the insider now directly owns 703,113 shares in the company, valued at approximately $10,251,387.54. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of Assembly Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. Acadian Asset Management LLC lifted its holdings in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 7,690 shares in the last quarter. FMR LLC increased its holdings in Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 3,635 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Assembly Biosciences during the 2nd quarter valued at about $6,421,000. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Stock Up 0.8 %

Shares of Assembly Biosciences stock opened at $16.70 on Thursday. Assembly Biosciences has a fifty-two week low of $7.69 and a fifty-two week high of $19.93. The company has a fifty day moving average of $16.74 and a 200 day moving average of $15.28.

Analysts Set New Price Targets

A number of analysts have commented on ASMB shares. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a report on Tuesday, September 24th. Jefferies Financial Group upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $2.00 to $35.00 in a research note on Friday, September 20th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.